Bristol-Myers Squibb secures patents on TREM-1 and Vista antibodies while publishing CD3 and CD19 bispecifics.
The filing
Bristol-Myers Squibb was granted US patents on November 10, 2026, for antibodies against human TREM-1 and for antibodies binding to Vista at acidic pH. The company also published applications on November 12, 2026, for CD3 binding molecules and for CD19 binding molecules including CD3- and CD19-bispecific T cell engagers.
This filing’s full text wasn’t read for this issue, so its claims and the applicant’s background aren’t shown. Both are in the record, under Sources.